Viewing Study NCT04867616



Ignite Creation Date: 2024-05-06 @ 4:05 PM
Last Modification Date: 2024-10-26 @ 2:03 PM
Study NCT ID: NCT04867616
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-13
First Post: 2021-04-27

Brief Title: A Study to Test the Efficacy Safety and Tolerability of Bepranemab UCB0107 in Patients With Mild Cognitive Impairment or Mild Alzheimers Disease AD
Sponsor: UCB Biopharma SRL
Organization: UCB Pharma

Study Overview

Official Title: A Patient- and Investigator-Blind Placebo-Controlled Study to Evaluate the Efficacy Safety and Tolerability of Bepranemab UCB0107 in Study Participants With Prodromal to Mild Alzheimers Disease AD Followed by an Open-Label Extension Period
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of the study is to investigate the effect of bepranemab versus vs placebo on the Clinical Dementia Rating Scale Sum of Boxes CDR-SB up to Week 80 in study participants with prodromal or mild Alzheimers Disease AD
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2020-005829-88 EUDRACT_NUMBER None None